Zika Virus Vaccine (DNA-Based) from Germany
This DNA-based Zika vaccine candidate uses a recombinant plasmid encoding the prM-E proteins of the Zika virus to induce neutralizing antibodies. It is an investigational vaccine for prevention of Zika virus infection. As a biotechnologically obtained vaccine, it is classified under tariff item 3002.49.00 as an 'other' vaccine.
Duty Rate — Germany → Canada
0%
Import Tips
• Obtain a Clinical Trial Application (CTA) approval from Health Canada for investigational use
• Provide documentation of the plasmid construction and quality control data
• Ensure the product is shipped at the required temperature and document any deviations